ISSN 1662-4009 (online)

ey0019.9-3 | Metabolic risk in childhood cancer | ESPEYB19

9.3. Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies

S Welsch , K Sawadogo , B Brichard , Ville de Goyet M de , Damme A Van , C Boulanger , P Lysy

sophie.welsch@uclouvain.be Diabet Med. 2022; 39: e14720. PMID: 34652870.Brief Summary: Childhood cancer survivors are at increased risk of hyperglycaemia and diabetes due to cancer treatments as asparaginase, steroids and total body irradiation. This single center, retrospective study analyzed the prevalence of hyperglycaemia in 267 patients treated between 2004 and 2019 for hematologic malignancie...

ey0017.2-6 | Neonatal Diabetes Mellitus | ESPEYB17

2.6. Intellectual disability in KATP channel neonatal diabetes

P Svalastoga , A Sulen , JR Fehn , SM Aukland , H Irgens , E Sirnes , SKE Fevang , E Valen , IB Elgen , PR Njolstad

To read the full abstract: Diabetes Care. 2020 Mar;43(3):526–533. doi: 10.2337/dc19-1013. Epub 2020 Jan 13. PMID:31932458Neonatal diabetes mellitus (NDM) is defined as diabetes that develops in the first 6 months of age. In Western countries, the most common causes of NDM are activating mutations in the KCNJ11/ABCC8 genes. Neurological dysfunction is also common (up to 30%) in pati...

ey0017.4-6 | Clinical Trials | ESPEYB17

4.6. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial

L Savendahl , T Battelino , M Brod , MH Rasmussen , R Horikawa , RV Juul , P REAL 3 study group Saenger

To read the full abstract: J Clin Endocrinol Metab ;105(4):e1847–e1861.The REAL 3 multicenter randomized, controlled, double-blind phase 2 study evaluated the efficacy and safety of different doses of once-weekly Somapacitan, compared to conventional once-daily GH in 59 prepubertal GHD children. The treatment period lasted 26 weeks and an additional extension to 52 weeks. At week 26, height velocity (HV) was 7.8, 10.9 and 13.1 cm/year, resp...

ey0017.4-10 | New perspectives | ESPEYB17

4.10. IGF-I in cord blood is predictive of final height in monozygotic twins with intratwin birth weight differences

C Kasner , S Schulte , F Schreiner , R Fimmers , B Stoffel-Wagner , P Bartmann , J Woelfle , B Gohlke

To read the full abstract: Clin Endocrinol (Oxf) 2020 May 13. doi: 10.1111/cen.14221. Online ahead of print.Children born either small for gestational age (SGA) or preterm usually do not achieve a final height (FH) in the mid-parental target height (MPTH) range, despite showing catch-up growth in the first years of life (1). The influence of intrauterine metabolic and hormonal factors has been p...

ey0017.7-4 | Clinical Guidance | ESPEYB17

7.4. Using kisspeptin to predict pubertal outcomes for youth with pubertal delay

YM Chan , MF Lippincott , P Sales Barroso , C Alleyn , J Brodsky , H Granados , SA Roberts , C Sandler , A Srivatsa , SB Seminara

To read the full abstract: Journal of clinical endocrinology and metabolism vol. 105,8 (2020): dgaa162. doi: https://academic.oup.com/jcem/article/105/8/dgaa162/5813981This longitudinal study (n =16) suggests that responses to kisspeptin administration could predict later pubertal outcomes for patients with delayed puberty. The management of...

ey0017.9-10 | Premature Aging, Cardiometabolic Fitness and Cardiovascular Damage | ESPEYB17

9.10. Childhood leukemia survivors and metabolic response to exercise: A pilot controlled study

C Pegon , E Rochette , N Rouel , B Pereira , E Dore , F Isfan , V Greze , E Merlin , J Kanold , P Duche

To read the full abstract: J Clin Med. 2020 Feb 19;9(2). pii: E562. e_rochette@chu-clermontferrand.frThis 5-month prospective case-control study was designed to evaluate the impairment of metabolic response to exercise in 20 childhood acute leukaemia survivors (CALSs), by the analysis of substrate oxidation during submaximal exercise, in comparison with 20 matched healthy controls.<p cla...

ey0017.9-14 | Cancer Treatment and Bone Health | ESPEYB17

9.14. High impact physical activity and bone health of lower extremities in childhood cancer survivors: A cross-sectional study of SURfit

SJ Zurcher , R Jung , S Monnerat , C Schindera , P Eser , C Meier , CS Rueegg , NX von der Weid , S Kriemler

To read the full abstract: Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32963. Epub ahead of print. susi.kriemlerwiget@uzh.chChildhood cancer survivors (CCS) can experience impaired bone health as a consequence of the disease itself, the specific treatments and/or associated chronic conditions. This cross-sectional study analyses baseline data from th...

ey0016.4-9 | New Perspectives | ESPEYB16

4.9. Low IGF-I bioavailability impairs growth and glucose metabolism in a mouse model of human PAPPA2 p.Ala1033Val mutation

M Fujimoto , M Andrew , L Liao , D Zhang , G Yildirim , P Sluss , B Kalra , A Kumar , S Yakar , V Hwa , A Dauber

To read the full abstract: Endocrinology. 2019;160:1363–1376.Pregnancy-associated plasma protein A2 (PAPP-A2) is a metalloproteinase which, by cleaving IGFBP-3 and IGFBP-5, releases free IGF-I from the ternary complexes and regulates its bioavailability. PAPPA2 gene mutations (p.D643fs25* and p.Ala1033Val) have recently been described in various members of two unrelated fam...

ey0016.5-2 | New Therapies and Novel Therapeutic Strategies | ESPEYB16

5.2. Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment

F Zaman , Y Zhao , B Celvin , HH Mehta , J Wan , D Chrysis , C Ohlsson , B Fadeel , P Cohen , L Savendahl

Abstract: FASEB J. 2019;33:4962–4974.In brief: Glucocorticoid-induced growth impairment is reverted by the mitochondrial peptide humanin in dexamethasone-treated mice without attenuation of anti-inflammatory effects.Comment: Humanin (HN) is a 24 aminoacid peptide that was originally discovered as a neuroprotective factor and later shown ...

ey0016.5-13 | Basic Science - Growth Plate | ESPEYB16

5.13. Differential aging of growth plate cartilage underlies differences in bone length and thus helps determine skeletal proportions

JC Lui , YH Jee , P Garrison , JR Iben , S Yue , M Ad , Q Nguyen , B Kikani , Y Wakabayashi , J Baron

Abstract: PLoS Biol. 2018 Jul 23;16(7):e2005263.In brief: In this article, Lui et al, make important observations related to the fundamental limits of longitudinal bone growth implicating the growth plate senescence program as a major regulator of bone size.Comment: A person’s right and left arms almost always grow to the same length, bu...